Your browser doesn't support javascript.
loading
Targeting the αVß3/NgR2 pathway in neuroendocrine prostate cancer.
Testa, Anna; Quaglia, Fabio; Naranjo, Nicole M; Verrillo, Cecilia E; Shields, Christopher D; Lin, Stephen; Pickles, Maxwell W; Hamza, Drini F; Von Schalscha, Tami; Cheresh, David A; Leiby, Benjamin; Liu, Qin; Ding, Jianyi; Kelly, William K; Hooper, D Craig; Corey, Eva; Plow, Edward F; Altieri, Dario C; Languino, Lucia R.
Affiliation
  • Testa A; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Quaglia F; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Naranjo NM; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Verrillo CE; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Shields CD; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Lin S; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Pickles MW; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Hamza DF; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Von Schalscha T; Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, United States.
  • Cheresh DA; Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, United States.
  • Leiby B; Division of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.
  • Liu Q; Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, United States.
  • Ding J; Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, United States.
  • Kelly WK; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Hooper DC; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Corey E; Department of Urology, University of Washington, Seattle, WA, United States.
  • Plow EF; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
  • Altieri DC; Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, United States.
  • Languino LR; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States.
Matrix Biol ; 124: 49-62, 2023 Dec.
Article in En | MEDLINE | ID: mdl-37956856
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Limits: Humans / Male Language: En Journal: Matrix Biol Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2023 Document type: Article Affiliation country: United States Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms Limits: Humans / Male Language: En Journal: Matrix Biol Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2023 Document type: Article Affiliation country: United States Country of publication: Netherlands